Elizabeth Hill, Ph.D.
Biostatistics
Research Interest
I have been a member of the Hollings Cancer Center’s (HCC’s) Biostatistics Shared Resource (BSR) since 2007 and was appointed the BSR’s director in 2017. In January 2020 I joined Eli Lilly and Company where I served as Statistical Director of the Early Phase Oncology Program, with direct oversight of the development and conduct of Lilly’s early phase (largely first-in-human) portfolio. I returned to MUSC in January 2021 to resume directorship of the BSR. In my 15+ years of BSR affiliation, I have collaborated with MUSC cancer center investigators spanning the oncology research continuum from designing bench experiments and early phase clinical trials to analyzing data from laboratories and large-scale epidemiologic databases. I have served as the biostatistics core director (PI or co-PI) for both multi-project (P01 and U54) and center grants (P30s), and I have a strong track record of continuous funding as co-investigator with numerous cancer center investigators.